Kesprazole 20 mg Delayed-Release Capsule

Kesprazole 20 mg Delayed-Release Capsules, manufactured by Ratnamani Healthcare Pvt. Ltd. and marketed in Nigeria by Kessington Pharma Ltd, provide a reliable treatment for acid-related gastrointestinal disorders. Each capsule contains 20 mg Omeprazole, a proton pump inhibitor (PPI) that targets H⁺/K⁺-ATPase in gastric parietal cells, effectively reducing gastric acid secretion.

NAFDAC-approved under registration number B4-8160 (since March 28, 2023), Kesprazole is formulated for delayed/prolonged release, ensuring enhanced protection against acid-induced discomfort. Available in convenient 2 × 7 and 1 × 14 capsules pack formats, this prescription-only medication supports patient compliance and consistent therapeutic coverage.

Ideal for managing GERD (gastroesophageal reflux disease), peptic ulcer disease, erosive esophagitis, and other conditions caused by excessive stomach acid, Kesprazole stands out for its effectiveness and regulatory compliance.

Short Product Description

Kesprazole 20 mg Capsules – NAFDAC-registered (NRN B4-8160) delayed-release Omeprazole by Kessington Pharma; effectively relieves acid reflux, ulcers, and GERD symptoms.

SEO-Optimized Bullet Highlights

• Active Ingredient: Omeprazole 20 mg (Proton Pump Inhibitor)

• Mechanism of Action: Delayed-release capsule reduces gastric acid secretion via H⁺/K⁺-ATPase inhibition

• Indications: GERD, peptic ulcers, erosive esophagitis, acid-related gastric conditions

• Regulatory Approval: NAFDAC Registered, NRN B4-8160 (Active since March 28, 2023)

• Manufacturer: Ratnamani Healthcare Pvt. Ltd. (India); Packaged and distributed by Kessington Pharma Ltd (Nigeria)

• Pack Sizes: 2 × 7-caps & 1 × 14-caps; Prescription-only medicine